Research Article |
Corresponding author: Mohamed Saadh ( mjsaadh@yahoo.com ) Academic editor: Magdalena Kondeva-Burdina
© 2023 Mohamed Saadh.
This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Citation:
Saadh M (2023) Anticancer and antiproliferative activity of ruthenium complex (II) bearing 3,3’-dicarboxy-2,2’-bipyridine ligand. Pharmacia 70(3): 803-807. https://doi.org/10.3897/pharmacia.70.e111508
|
Even though significant progress has been made in cancer treatment, there is always room for improvement. The experimental drug Ruthenium Complex II shows promise as a cancer treatment. In this article, the dichloro-3,3’-dicarboxy-2,2’-bipyridyl bis(dimethylsulphoxide)ruthenium(II) [RuCl2(3,3’-dcbpy)(DMSO)2], have been synthesized, characterized, and studied for its anticancer activity against MDA-MB-231 and MRC-5 cell lines, as well as its mechanisms of action and selectivity. According to research, [RuCl2 (3,3’-dcbpy)(DMSO)2], is highly cytotoxic to the MDA-MB-231 and minimum cytotoxic to MRC-5 cell lines, with IC50 values of 5.95 and 579.6 μg/ml, respectively. Ruthenium Complex II is exceptionally effective at destroying cancer cells while causing minimal harm to healthy cells. RuCl2(3,3’-dcbpy)(DMSO)2] caused apoptosis, which was confirmed by the activation of caspase-3. Ruthenium complexes hold great promise as powerful anticancer agents. Their unique mechanisms of action, ability to selectively target cancer cells, and versatility in chemical structure make them attractive candidates for the development of targeted therapies.
Anticancer agents, coordination complexes, cytotoxic activity, ruthenium complex, tumor cell lines
Cancer, a complex and devastating disease, often demands innovative treatments due to limitations of traditional drugs that may cause systemic toxicity and drug resistance (
Ruthenium complexes have emerged as intriguing candidates for anticancer therapy due to their unique chemical properties and diverse mechanisms of action (
MDA-MB-231 is a widely studied triple-negative breast cancer cell line known for its aggressive behavior, making it suitable to investigate the potential efficacy of anticancer agents like ruthenium complexes (
In this study, the dichloro-3,3’-dicarboxy-2,2’-bipyridyl bis(dimethylsulphoxide)ruthenium(II) [RuCl2(3,3’-dcbpy)(DMSO)2], was synthesized, characterized using FT-IR and X-ray crystallography. This study aims to synthesize a novel ruthenium complex and characterize it using FT-IR, UV, and NMR techniques. Subsequently, assess the anticancer potential of a ruthenium complex against MDA-MB-231 cells by determining its IC50 value and evaluating its impact on caspase 3 activity, shedding light on its cytotoxic and apoptotic effects.
According to published procedures, 3,3’-dicarboxy-2,2’-bipyridine and [RuCl2 (DMSO)4] were synthesized. Following procedures outlined in the literature, 1,4-dioxane (Merck) was purified and dried (Armarego W L F, 2017). Ethanol and methanol were redistillated in an atmosphere of nitrogen. All operations were performed in the N2 atmosphere. The tested samples were dissolved using distilled water as the solvent.
A suspension of 3,3’-dcbpy compound (0.121 g, 0.500 mmol) in dry ethanol (20 mL) was added to a suspension of [RuCl2(DMSO)4] (0.242 g, 0.500 mmol) in dry ethanol (20 mL). Two hours were spent heating the reaction mixture to reflux under a nitrogen flow. During this time, the color of the solution changed to a brown-red hue. After allowing the reaction to cool to room temperature, it was filtered. The solvents were eliminated in order to achieve dryness. The residual solid was dissolved in minimal dry methanol and then filtered. Adding 20 mL of diethyl ether produced a brown solid. The product was then filtered, washed with diethyl ether (210 mL), and vacuum-dried at 60 °C for four h (
The infrared spectra were recorded on KBr discs using a Nicolet Impact-400 FT-IR spectrometer. On a Bruker AVANCE III-500 MHz spectrometer, the 1H and 13C NMR spectra were acquired. The Philip-Harris melting point apparatus was used to determine melting points. Using a Cary 100 Bio UV-Vis spectrophotometer, UV-Visible spectra were generated for 1.0 10-5 M solutions in CH2Cl2 at 25 °C (
MRC-5 and MDA-MB-231 cells were obtained from ECACC. MCF-7 and MRC-5 cells were cultured in DMEM supplemented with 10% heat-inactivated fetal bovine serum, L-glutamine (2 mM), and penicillin/streptomycin (100 U/ml, 100 g/ml) (
After 12 hours of attachment, 2.0 ml of fresh medium containing 2, 5, 10, 20, 50, and 100 g/ml [RuCl2(3,3’-dcbpy)(DMSO)2] was added to six-well plates containing 4 × 104 cells/ml. The biochemistry of cells was evaluated 24 hours after treatment (
In brief, incubate 1 × 104 cells with Ru(3,3’-dcbpy) (DMSO)2 Cl2] at concentrations of 2, 5, 10, 20, 50, and 100 µg/ml for 72 hours. Wells were incubated with MTT for four hours after exposure. A multi-well plate reader (Bio-Tek Instrument, USA) measured optical density (OD) at 570 nm with a reference wavelength of 630 nm after dissolving MTT crystals in 100 µl of DMSO solution (
RIPA reagent was used to extract total protein from MDA-MB-231 cells after 48 hours of treatment with [Ru(3,3’-dcbpy) (DMSO)2 Cl2] (25, 50, and 150 µg/mL). A commercial kit (KeyGen Biotechnology, Nanjing, China) and an ELISA reader (ELX800, Promega, US) measured caspase-3 activity at 405 nm.
SPSS 19.0 performed an unpaired Student’s t-test on mean standard deviation and P value data. P < 0.05 was significant.
The new ruthenium complex was made by directly reacting RuCl2(DMSO)4 with 3,3’-dicarboxy-2,2’-bipyridine in dry ethanol. The [RuCl2(3,3’-dcbpy)(DMSO)2] is formed by mixing RuCl2(DMSO)4 with one equivalent of ligand (Equation 1). Microelemental analysis confirmed the complex formulation. This complex was characterized by FT-IR and UV-Vis.
The brown complex [RuCl2(3,3’-dcbpy)(DMSO)2] is soluble in water, methanol, ethanol, acetone, tetrahydrofuran, and dimethylsulphoxide but not in dichloromethane, chloroform, petroleum ether, or diethyl ether.
Table
(N-P), [RuCl2(DMSO)4], and [RuCl2(3,3’-dcbpy)(DMSO)2] complexes infrared spectral data.
Mode | Compounds | ||
---|---|---|---|
[RuCl2(DMSO)4] | (3,3’-dcbpy) | [RuCl2(3,3’-dcbpy)(DMSO)2] | |
nO-H | – | 3392 | 3422 |
nC-H (Aromatic) | – | 3073 | 3076 |
nC-H (Aliphatic) | 3002, 2920 | – | 2919, 2599 |
nC-C (Aromatic) | – | 1578. 1433 | 1573, 1419 |
nC=O | – | 1717 | 1719 |
nS=O (S-bonded) | 1100, 1021 | – | 1088, 1016 |
nS=O (O-bonded) | 927 | – | – |
The MTT assay assessed doxorubicin’s cytotoxicity. As a positive control, doxorubicin showed IC50 values of 5.15 and 7.45 μg/m against MDA-MB-231 and MRC5. The [RuCl2(3,3’-dcbpy)(DMSO)2] exhibits IC50 values of 5.95 and 579.6 μg/ml against MDA-MB-231 and MRC5, respectively (Table
To determine [RuCl2(3,3’-dcbpy)(DMSO)2] cytotoxic mechanism, caspase3 activity, the apoptosis executor, was measured. Activation of caspase 3 by [RuCl2(3,3’-dcbpy)(DMSO)2] (P < 0.05) is dose-dependent (Fig.
Ruthenium complexes exhibit unique chemical properties that enable targeted interactions with cancer cells, resulting in effective cytotoxicity (
Ruthenium exhibits cancer cell specificity, minimizing impact on normal cells. Its selective behavior holds promise for targeted therapies with reduced side effects (
In conclusion, [RuCl2(3,3’-dcbpy)(DMSO)2] demonstrated significant cytotoxicity against MDA-MB-231. Ruthenium exhibits cancer cell specificity, minimizing impact on normal cells. Moreover, the fact that it activates caspase-3 in a dose-dependent manner suggests an apoptotic mechanism of action, showing that it could be a promising anticancer agent. However, we need to do more research to fully understand its mechanism of action.